Renal Anemia

Conflicts and Controversies

Nonfiction, Health & Well Being, Medical, Specialties, Internal Medicine, Nephrology, Hematology
Cover of the book Renal Anemia by , Springer Netherlands
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9789401599986
Publisher: Springer Netherlands Publication: June 29, 2013
Imprint: Springer Language: English
Author:
ISBN: 9789401599986
Publisher: Springer Netherlands
Publication: June 29, 2013
Imprint: Springer
Language: English

Is the nephrology community facilitating excess cardiovascular deaths in patients with kidney failure and anemia by treating to a subnormal hematocrit? Why have clinicians and nephrologists permitted health insurance companies and the government to decide when anemia therapy should begin in persons with progressive kidney failure? Is iron the only variable that can be manipulated to maximize response to recombinant erythropoietin? Are we using too much intravenous iron in kidney failure patients, and is oral iron supplementation worthless in sustaining iron stores during long-term erythropoietin treatment? When does left ventricular hypertrophy begin to emerge in patients with progressive renal disease and is there convincing evidence that anemia is a significant cause of LVH in this setting? Is darbepoetin alfa, a new novel, long-acting erythropoietin, really superior to recombinant erythropoietin? This book is a compilation of proceedings from a conference in Brooklyn convened to address these and other controversial and unresolved issues in renal anemia management.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Is the nephrology community facilitating excess cardiovascular deaths in patients with kidney failure and anemia by treating to a subnormal hematocrit? Why have clinicians and nephrologists permitted health insurance companies and the government to decide when anemia therapy should begin in persons with progressive kidney failure? Is iron the only variable that can be manipulated to maximize response to recombinant erythropoietin? Are we using too much intravenous iron in kidney failure patients, and is oral iron supplementation worthless in sustaining iron stores during long-term erythropoietin treatment? When does left ventricular hypertrophy begin to emerge in patients with progressive renal disease and is there convincing evidence that anemia is a significant cause of LVH in this setting? Is darbepoetin alfa, a new novel, long-acting erythropoietin, really superior to recombinant erythropoietin? This book is a compilation of proceedings from a conference in Brooklyn convened to address these and other controversial and unresolved issues in renal anemia management.

More books from Springer Netherlands

Cover of the book Generating Images of Stratification by
Cover of the book Rasch Analysis in the Human Sciences by
Cover of the book Modelling Rock Fracturing Processes by
Cover of the book Physics and Chemistry of Partially Molten Rocks by
Cover of the book The Spiral Galaxy M33 by
Cover of the book Action: An Analysis of the Concept by
Cover of the book Heidegger’s Metahistory of Philosophy: Amor Fati, Being and Truth by
Cover of the book Organic Acidurias by
Cover of the book Effective Group Work in Primary School Classrooms by
Cover of the book Electrocardiographic Body Surface Mapping by
Cover of the book Child Nutrition in South East Asia by
Cover of the book Seismic Modelling and Pattern Recognition in Oil Exploration by
Cover of the book Influenza Models by
Cover of the book Exercise Testing and Training in Coronary Heart Disease by
Cover of the book Plant Molecular Biology Manual by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy